Discussion about this post

User's avatar
Steve Cheung's avatar

Yet another great trial by the Kings College group. This along with the initial Orbita should set the new bar for proper sham placebo control for all device trials.

This trial confirms the long-held belief that PCI “works” for symptoms. However, I disagree with some who have interpreted this trial to suggest PCI should become the first option for angina control. Combined with Orbita 1, it could perhaps be argued that PCI offers benefit to Med naive patients but may offer less benefit to Med refractory patients. While I think this is a defensible position, I would not move to a default strategy of PCI for symptom control on the basis of such a short follow up study.

Expand full comment
Julia's avatar

It would be interesting to see if there’s any relevance to the 2 strokes in the PCI arm vs 0 in the placebo arm…

Expand full comment
4 more comments...

No posts